Setback
Medtronic executives said supply chain and manufacturing problems slowed Hugo's rollout after the pandemic.
A delay, pause or setback
What the source says
“Supply chain issues and manufacturing problems hindered its rollout following the pandemic, executives said late in 2022.”
What it means
Hugo, from Medtronic, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. A setback stays on the record next to the milestones; the stage moves down only when the rules say so.
Human help: The maker hasn't said whether people help it remotely.
More on Hugo
- The FDA cleared a Medtronic vessel-sealing instrument for use with Hugo. Medtronic expects Hugo to pass 50,000 completed operations this financial year.
- Medtronic agreed to sell Cornerstone Robotics' Sentire surgical robot alongside Hugo in some markets outside the US, as part of a deal of about $700 million.
- Medtronic asked the FDA to clear Hugo for general surgery, including hernia repair, and for gynecologic surgery.
- The first US operation with Hugo, a prostate removal, was done at Cleveland Clinic in February 2026.
- The FDA cleared Hugo for soft-tissue urology operations, such as on the prostate, kidney and bladder.
- Hugo received the CE mark, which allows it to be sold in Europe.